Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS prenyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Odeniyide, Patience, Yohe, Marielle E., Pollard, Kai, Vaseva, Angelina V., Calizo, Ana, Zhang, Lindy, Rodriguez, Fausto J., Gross, John M., Allen, Amy N., Wan, Xiaolin, Somwar, Romel, Schreck, Karisa C., Kessler, Linda, Wang, Jiawan, Pratilas, Christine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122815/
https://www.ncbi.nlm.nih.gov/pubmed/35459782
http://dx.doi.org/10.1038/s41388-022-02305-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122815/
https://www.ncbi.nlm.nih.gov/pubmed/35459782
http://dx.doi.org/10.1038/s41388-022-02305-x

Ejemplares similares